Abstract:To investigate the potential role of CTLA4Ig gene and OX40Ig protein in inducing transplantation tolerance and the mechanisms thereof.Thirty Lewis rats underwent transplantation of the hearts of DA rats and then randomly divided into five equal groups: control group, blank virus AdEGFP treated group (adenovirus containing EGFP at the dose of 1-5 x 10(9) pfu/ml was infused via portal vein immediately after the operation), AdCTLA4Ig treated group, AdOX40Ig treated group, and AdCTLA4Ig-IRES-OX40Ig treated group. The cardiac allograft survival was monitored by daily palpation. The total cessation of beating was defined as rejection and was confirmed by histology. Peripheral venous blood samples were collected 0, 3, 7, 10, 14, 21 and 28 days after the administration of adenovirus. ELISA was used to detect the expression of CTLA4Ig and OX40Ig. Twenty days after the heart transplantation single splenocyte suspension was prepared from surviving Lewis rats to be used as responder. The spleens of the normal donor-DA rats and the third strain DA rats to prepare single cell suspension of the same density to perform mixed lymphocyte reaction (MLR). Then recombinant IL-2 was added into the mixed MLR system to observe t\if the MLR could be reversed. Twenty days after the heart transplantation the splenocytes of the tolerating Lewis rats were injected into the lingual vein of the normal Lewis rats to observe the delayed type hypersensitivity (DTH) of the transferred Lewis rat to normal rat splenocytes. RT-PCR was used to detect the mRNA expression of IL-2, interferon-gamma, IL-4, and IL-10.The survival time of the AdCTLA4Ig-IRES-OX40Ig treated group was 151.5 d +/- 42.6 d, significantly longer than those of the AdOX40Ig treated group (60.2 d +/- 11.4 d (P = 0.003), AdCTLA4Ig (43.2 d +/- 11.1 d, P = 0.0026), control group (5.7 d +/- 0.5 d, P = 0.000 43), and AdEGFP treated group (5.2 d +/- 0.4 d, P = 0.000 43). CTLA4Ig and/or OX40Ig proteins were expressed at a high level in the adenoviral treated rats. Compared with the control group the splenocytes of the AdCTLA4Ig-IRES-OX40Ig, AdCTLA4Ig, and AdOX40Ig treated groups displayed donor-specific hyporesponsiveness (P = 0.0016, 0.0026 and 0.001), which could be partly reversed by the addition of exogenous IL-2. Moreover, the hyporesponsiveness could be transferred to the same strain rats through adoptive transfer. In comparison with the normal controls, the expression of Th1 type cytokines, such as IL-2 and IFN-gamma, was significantly decreased in the tolerating rats and significantly increased in the rats with rejection; however the expression of the Th2 type cytokines, such as IL03 and IL-10, was significantly increased in the tolerating rats and significantly decreased in the rats with rejection, showing a deviation of Th1/Th2 type cytokines.AdCTLA4Ig-IRES-OX40Ig-mediated genes transfer renders prolonged expression of CTLA4Ig and OX40Ig in Lewis recipient rats, leading to a long-term survival of cardiac allografts. The induced tolerance is donor-specific, and the mechanisms may be associated with T cell anergy, deviation of Th1/Th2, and the regulatory T cells.

STABLE EXPRESSION OF INTERLEUKIN-10 SUPPRESSES THE DEVELOPMENT OF CHRONIC ALLOGRAFT REJECTION IN RATS:

Inhibition of Alloimmune Response Induced by a Plasmid Vector-Transducted IL-10 Gene Therapy after Heart Transplantation in Mice

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Induction of lymphocyte apoptosis in rat liver allograft by adenoviral gene transfection of human interleukin-10.

Prolonged Amelioration of Acute Lung Allograft Rejection by Overexpression of Human Interleukin-10 under Control of A Long Acting Ubiquitin C Promoter in Rats

Effects of TGF-β1 on Expression of IL-10 in Immunological Rejection after High-Risk Penetrating Keratoplasty

Adeno-Associated Viral Vector-Mediated Interleukin-10 Prolongs Allograft Survival in A Rat Kidney Transplantation Model

Recombinant Adenovirus Vector Ad-hIL-10 Protects Grafts from Cold Ischemia-Reperfusion Injury Following Orthotopic Liver Transplantation in Rats.

Transduction of Interleukin-10 Through Renal Artery Attenuates Vascular Neointimal Proliferation and Infiltration of Immune Cells in Rat Renal Allograft.

Interleukin 10 Attenuates Neointimal Proliferation And Inflammation In Aortic Allografts By A Heme Oxygenase-Dependent Pathway

Synergistic Effect of Low Dose Cyclosporine A and Human Interleukin 10 Overexpression on Acute Rejection in Rat Lung Allotransplantation.

Prolonged Amelioration Of Acute Lung Allograft Rejection By Sequential Overexpression Of Human Interleukin-10 And Hepatocyte Growth Factor In Rats

Bone marrow stem cells modified with human interleukin 10 attenuate acute rejection in rat lung allotransplantation.

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Lentivirus-mediated gene transfer of viral interleukin-10 delays but does not prevent cardiac allograft rejection

leukin-15 (IL-15) production during acute rejection following heart transplantation in mice. Inbred male Balb/c (H-2d) and C57BL/6 (H-2b) mice were used to establish a heterotopic intra-abdominal cardiac transplantation model. The mice were divided in four groups: syngeneic control, allogeneic acute

Adenovirus-mediated CTLA4Ig and OX40Ig gene transfer induces long-term survival of cardiac allografts in rats]

Prevention of Acute and Chronic Rejection of Rat Heart Allografts by Oral Administration of Tolerogenic Donor Recipient Allochimeric Class I Mhc Proteins

Adenovirus-mediated interleukin-10 gene transfer inhibits post-transplant fibrous airway obliteration in an animal model of bronchiolitis obliterans

Selective Immunosuppression with Anti-Interleukin-2 Receptor-Targeted Therapy - Helper and Suppressor-Cell Activity in Rat Recipients of Cardiac Allografts